Part D Plan To Adjust Cost Sharing For Biosimilars Questioned By PhRMA
Executive Summary
PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.
You may also be interested in...
Biosimilar/Brand Patent Settlements Need US Antitrust Review, PBM Says
Federal Trade Commission and Department of Justice should be able to scrutinize settlements between biologic reference product sponsors and biosimilar developers, Express Scripts says; PBM's policy proposals for coming year include safe harbor for certain value-based reimbursement arrangements, and mandatory electronic prescribing and dispensing limits for opioids.
Biosimilar/Brand Patent Settlements Need US Antitrust Review, PBM Says
Federal Trade Commission and Department of Justice should be able to scrutinize settlements between biologic reference product sponsors and biosimilar developers, Express Scripts says; PBM's policy proposals for coming year include safe harbor for certain value-based reimbursement arrangements, and mandatory electronic prescribing and dispensing limits for opioids.
Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA
Biopharma manufacturers dispute predictions that passing through rebates at the point-of-sale in Medicare Part D would increase government spending. Pharmacy benefit managers argue the policy would violate the Part D statute and the Trade Secrets Act.